<DOC>
	<DOCNO>NCT02897245</DOCNO>
	<brief_summary>Treatment Chronic Myeloid Leukemia ( CML ) revolutionize use tyrosine kinase inhibitor include imatinib mesylate ( Gleevec , Novartis Laboratories ) . Two inhibitor BCR-ABL kinase currently market France , nilotinib ( Tasigna® , Novartis Laboratories ) first second-line treatment dasatinib ( SPRYCEL® , Bristol-Myers Squibb Laboratories ) second line . Achieving complete molecular response ( CMR ) patient Chronic Myeloid Leukemia ( CML ) treat tyrosine kinase inhibitor may currently regard ultimate level reduction residual disease . The pilot Stop Imatinib study open way french prospective study stop imatinib , STIM study . The result STIM study show almost 60 % patient exhibit molecular relapse , frequently within first 6 month discontinuation . The parameter statistically associate loss complete molecular response Sokal score diagnosis total duration treatment imatinib . Criteria define molecular relapse treatment free remission patient well define validate . The aim study validate loss major molecular response robust criterion TKI resumption . The patient 's population CML patient offer discontinue therapy outside STIM strial .</brief_summary>
	<brief_title>A Study Tyrosine Kinase Inhibitors Discontinuation</brief_title>
	<detailed_description />
	<criteria>Patient Chronic Myelogenous leukemia mors 18 year old intentionally stop treatment tyrosine kinase inhibitor inclusion prospective study non intentionally stop ( adverse event ) Stop disease progression Death patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Myelogenous</keyword>
	<keyword>Chronic</keyword>
	<keyword>BCR-ABL Positive</keyword>
</DOC>